1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
BARDA BioTools Innovator VANGUARD 2026 Accelerator Track for AI-Enabled Biomedical Tools Drug Discovery and Diagnostics is sponsored by Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services. BioTools Innovator VANGUARD is the Enabling Technologies hub of the BARDA Accelerator Network supporting startups developing medical countermeasures for biothreats and pandemic preparedness.
Get alerted about grants like this
Get emailed when new opportunities from “Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Leading accelerator program for life science enabling technologies. Enabling Technologies Hub BARDA Accelerator Network Enabling the Development of Innovations in Drug Discovery and Development, Biomanufacturing, and Bioanalytic and Diagnostic Instrumentation to Improve Clinical Research and Response BioTools Innovator VANGUARD is at the forefront of innovation for enabling life science technologies.
VANGUARD supports biotools startups to develop solutions that improve drug discovery and development; to increase biomanufacturing speed, capacity, portability, and scalability; to enhance sample processing efficiency and diagnostic assay capabilities; and to accelerate bioanalysis of emerging pathogens.
VANGUARD stands ready to support startups in deploying innovative medical countermeasures that enhance the United States’ readiness for public health emergencies.
VANGUARD is a joint initiative between BioTools Innovator, the world’s first-ever accelerator focused on life science research tools, and the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services.
BioTools Innovator VANGUARD Opportunities BioTools Innovator VANGUARD consists of two programs, a health security-focused accelerator track as part of the core BioTools Innovator annual cohort, and a specialized technical development, evaluation, and validation non-dilutive funding opportunity. Companies may apply to either or both programs.
BioTools Accelerator Program Track The BioTools Innovator VANGUARD Accelerator will select up to 10 companies annually to participate in a specialized track of the BioTools Innovator accelerator, a four-month program.
Non-Dilutive Funding Program BioTools VANGUARD provides non-dilutive funding to support the Development, Evaluation, and Validation program for technologies that advance BARDA’s mission to enhance pandemic preparedness and health security.
Through Level UP-XR: Training for Biopharmaceutical Manufacturing Technicians, BioTools Innovator VANGUARD will provide non-dilutive funding to innovative CDMO and XR companies creating next-generation training solutions that strengthen the biopharmaceutical manufacturing workforce.
BioTools Innovator VANGUARD Opportunities BioTools Innovator VANGUARD consists of two programs, a wraparound Accelerator program as part of the core BioTools Innovator annual cohort, and a specialized product Development, Evaluation, and Validation (DEV) funding opportunity. Companies may apply to either or both programs.
BioTools Accelerator Program Track The BioTools Innovator VANGUARD Accelerator will select up to 10 companies annually to participate in a specialized track of the BioTools Innovator accelerator, a four-month program.
Non-Dilutive Funding Program BioTools VANGUARD provides non-dilutive funding to support the Development, Evaluation, and Validation program for technologies that advance BARDA’s mission to enhance pandemic preparedness and health security.
Challenges & Competitions Through Level UP-XR: Training for Biopharmaceutical Manufacturing Technicians, BioTools Innovator VANGUARD will provide non-dilutive funding to innovative CDMO and XR companies creating next-generation training solutions that strengthen the biopharmaceutical manufacturing workforce.
Through ReadyDetect: Blood Sampling Competition, BioTools Innovator VANGUARD will award over $5M in prizes to companies advancing next-generation capillary blood collection and processing devices for diagnostics at the point of need — home, field, and resource-limited settings. Congratulations to our 2026 VANGUARD Cohort!
BioTools Innovator Awards $1M through 2026 VANGUARD Funding Program —BioTools Innovator VANGUARD supports development & validation projects of 5 startups through non-dilutive funding awards. —… https://biotoolsinnovator. org/wp-content/uploads/2026/06/VANGUARD-Dev-OP1-2026-Companies-banner-2026.
png https://secure. gravatar. com/avatar/e13bab7c2cdd41999c00a193593bdb0c4c93c99c95ac7ba940e5754e744a312d?
s=96&d=mm&r=g BioTools Innovator VANGUARD Launches ReadyDetect Blood Sampling Collection Prize Competition A new prize competition seeks innovative blood collection and sample preparation technologies to expand access… https://biotoolsinnovator. org/wp-content/uploads/2026/06/ReadyDetect-PR-Blog-Featured-Image-June-2026. png https://secure.
gravatar. com/avatar/e13bab7c2cdd41999c00a193593bdb0c4c93c99c95ac7ba940e5754e744a312d? s=96&d=mm&r=g BioTools Innovator VANGUARD Launches New Funding Opportunity to Enhance Biopharmaceutical Manufacturing Through Extended Reality Technology Los Angeles - December 2, 2025 - BioTools Innovator (BTI) VANGUARD, in partnership with the… https://biotoolsinnovator.
org/wp-content/uploads/2025/12/BTI-XR-Vanguard. png https://secure. gravatar.
com/avatar/e13bab7c2cdd41999c00a193593bdb0c4c93c99c95ac7ba940e5754e744a312d? s=96&d=mm&r=g BioTools Innovator Begins VANGUARD Program with Inaugural Accelerator Track Cohort and Nearly $1M in Funding Awards https://biotoolsinnovator. org/wp-content/uploads/2025/08/vanguard-2025-banner.
png https://secure. gravatar. com/avatar/e13bab7c2cdd41999c00a193593bdb0c4c93c99c95ac7ba940e5754e744a312d?
s=96&d=mm&r=g The BARDA Accelerator Network In Partnership with the Biomedical Advanced Research and Development Authority The BARDA Accelerator Network aims to provide comprehensive support to health security innovators, startups and BARDA portfolio companies through wrap-around accelerator services, technical and business/commercialization expertise, and resources.
The network will facilitate the rapid development, evaluation, validation and commercialization of medical countermeasures. Learn more at the BARDA Accelerator Network . BARDA Accelerator Network Hubs The BARDA Accelerator Network, made up of five Hubs, is built to drive growth in the startup ecosystem by speeding up the creation and market entry of cutting-edge health security solutions.
Each Hub sources promising early-stage innovations within their specialized technology areas and offers funding to evaluate the feasibility of these concepts and provides resources for commercialization, helping to fast-track product development and validation.
BioTools Innovator VANGUARD is at the forefront of biomanufacturing innovation, enabling life science tools startups to develop solutions that improve drug discovery and development; increase speed, capacity, portability, and scalability; and improve clinical research and clinical care coordination.
Diagnostics & Medical Devices The International Consortium for Research, Engineering, Acceleration of Technology Excellence (I-CREATE) Hub supports the development and acceleration of novel diagnostics and medical devices to detect, prevent, or respond to medical consequences that result from health security threats.
Focus on innovations that can improve the detection, diagnosis, treatment, and informed outcomes in pediatric/neonatal populations and immunocompromised populations to enable health equity solutions in traditionally underrepresented communities and low-resource settings.
Therapeutics and Vaccines The Vaccine Innovations and Therapeutics Acceleration Launchpad (VITAL) Hub will support the development and acceleration of next-generation therapeutic and vaccine platforms and technologies. Focus on the development and application of digital health tools to empower people to prepare for and respond to health security threats and improve the continuum of clinical care.
BioTools Innovator VANGUARD is at the forefront of biomanufacturing innovation, enabling life science tools startups to develop solutions that improve drug discovery and development; increase speed, capacity, portability, and scalability; and improve clinical research and clinical care coordination.
Diagnostics & Medical Devices The International Consortium for Research, Engineering, Acceleration of Technology Excellence (I-CREATE) Hub supports the development and acceleration of novel diagnostics and medical devices to detect, prevent, or respond to medical consequences that result from health security threats.
Focus on the development and application of digital health tools to empower people to prepare for and respond to health security threats and improve the continuum of clinical care.
Focus on innovations that can improve the detection, diagnosis, treatment, and informed outcomes in pediatric/neonatal populations and immunocompromised populations to enable health equity solutions in traditionally underrepresented communities and low-resource settings.
Therapeutics and Vaccines The Vaccine Innovations and Therapeutics Acceleration Launchpad (VITAL) Hub will support the development and acceleration of next-generation therapeutic and vaccine platforms and technologies. For additional information and questions, please contact vanguard@biotoolsinnovator. org .
According to the current listing, eligibility includes: U. S. and international biotools startups and university-backed projects developing drug discovery platforms, biomanufacturing tools, or bioanalytic and diagnostic instruments aligned with BARDA's biosecurity mission. Confirm the full requirements in the official notice before applying.
The current listing shows non-dilutive funding awards of $50,000 to $200,000 per company to support technical development, evaluation, and validation projects, plus participation in a four-month accelerator. Up to 10 companies selected annually. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for BARDA BioTools Innovator VANGUARD 2026 Accelerator Track for AI-Enabled Biomedical Tools Drug Discovery and Diagnostics are due December 31, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
BARDA BioTools Innovator VANGUARD 2026 Accelerator Track for AI-Enabled Biomedical Tools Drug Discovery and Diagnostics is funded by Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services. Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
The joint NSF-NIH Smart Health and Biomedical Research solicitation supports high-risk, high-reward AI/data science work in health — $300K per year for four years, with 20+ NIH institutes participating. Here is how the program actually selects winners.
Read articleThe STOMP program funds measurement tools and removal therapies for microplastics in human tissue. Proposals due June 22. Eligibility, phases, and strategy.
Read articleSAMHSA distributed $794M in block grants for mental health and substance abuse programs. Here's how community organizations can access these funds through state subgrant processes.
Read article